• Caridad Díaz, Cristina Jiménez-Luna, Carmelo Diéguez-Castillo, Ariadna Martín, José Prados, José Luis Martín-Ruíz, Olga Genilloud, Francisca Vicente, José Pérez Del Palacio, and Octavio Caba.
• Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores, 18012 Granada, Spain.
• Medicina (Kaunas). 2021 Aug 26; 57 (9).

AbstractBackground and Objectives: The clinical manifestations and course of chronic pancreatitis (CP) are often nonspecific and variable, hampering diagnosis of the risk of exocrine pancreatic insufficiency (EPI). Development of new, reproducible, and non-invasive methods to diagnose EPI is therefore a major priority. The objective of this metabolomic study was to identify novel biomarkers associated with EPI. Materials and Methods: We analyzed 53 samples from patients with CP, 32 with and 21 without EPI, using an untargeted metabolomics workflow based on hydrophilic interaction chromatography coupled to high-resolution mass spectrometry. Principal component and partial least squares-discriminant analyses showed significant between-group differentiation, and univariate and multivariate analyses identified potential candidate metabolites that significantly differed between samples from CP patients with EPI and those without EPI. Results: Excellent results were obtained using a six-metabolic panel to diagnose the presence of EPI in CP patients (area under the ROC curve = 0.785). Conclusions: This study confirms the usefulness of metabolomics in this disease setting, allowing the identification of novel biomarkers to differentiate between the presence and absence of EPI in CP patients.

13 keywords...

hide…